



Molecular Characterization and Sterol Profiles Identify Nonsynonymous Mutations in *ERG2* as a Major Mechanism Conferring Reduced Susceptibility to Amphotericin B in *Candida kefyr*

Mohammad Asadzadeh,^a Wadha Alfouzan,^a Josie E. Parker,^b  Jacques F. Meis,^{c,d,e} Steven L. Kelly,^f Leena Joseph,^a  Suhail Ahmad^a

^aDepartment of Microbiology, Faculty of Medicine, Kuwait University, Safat, Kuwait

^bMolecular Biosciences Division, School of Biosciences, Cardiff University, Cardiff, United Kingdom

^cDepartment of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands

^dCenter of Expertise in Mycology, Radboudumc, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands

^eDepartment of Internal Medicine, Excellence Center for Medical Mycology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany

^fInstitute of Life Science, Faculty of Health, Medicine and Life Sciences, Swansea University, Swansea, Wales, United Kingdom

ABSTRACT The molecular basis of reduced susceptibility to amphotericin B (rs-AMB) among any yeasts is poorly defined. Genetic alterations in genes involved in ergosterol biosynthesis and total cell sterols were investigated among clinical *Candida kefyr* isolates. *C. kefyr* isolates ($n = 81$) obtained from 74 patients in Kuwait and identified by phenotypic and molecular methods were analyzed. An Etest was initially used to identify isolates with rs-AMB. Specific mutations in *ERG2* and *ERG6* involved in ergosterol biosynthesis were detected by PCR sequencing. Twelve selected isolates were also tested by the SensiTitre Yeast One (SYO), and total cell sterols were evaluated by gas chromatography-mass spectrometry and *ERG3* and *ERG11* sequencing. Eight isolates from 8 patients showed rs-AMB by Etest, including 2 isolates with additional resistance to fluconazole or to all three antifungals. SYO correctly identified 8 of 8 rs-AMB isolates. A nonsynonymous mutation in *ERG2* was detected in 6 of 8 rs-AMB isolates but also in 3 of 73 isolates with a wild-type AMB pattern. One rs-AMB isolate contained a deletion (frameshift) mutation in *ERG2*. One or more nonsynonymous mutations was detected in *ERG6* in 11 of 81 isolates with the rs-AMB or wild-type AMB pattern. Among 12 selected isolates, 2 and 2 isolates contained a nonsynonymous mutation(s) in *ERG3* and *ERG11*, respectively. Ergosterol was undetectable in 7 of 8 rs-AMB isolates, and the total cell sterol profiles were consistent with loss of *ERG2* function in 6 rs-AMB isolates and loss of *ERG3* activity in another rs-AMB isolate. Our data showed that *ERG2* is a major target conferring rs-AMB in clinical *C. kefyr* isolates.

IMPORTANCE Some yeast species exhibit intrinsic resistance or rapidly acquire resistance to azole antifungals. Despite >50 years of clinical use, resistance to amphotericin B (AMB) among yeast species has been extremely rarely reported until recently. Reduced susceptibility to AMB (rs-AMB) among yeast species is, therefore, a matter of serious concern due to the availability of only four classes of antifungal drugs. Recent studies in *Candida glabrata*, *Candida lusitanae*, and *Candida auris* have identified *ERG* genes involved in ergosterol biosynthesis as the major targets conferring rs-AMB. The results of this study also show that nonsynonymous mutations in *ERG2* impair its function, abolish ergosterol from *C. kefyr*, and confer rs-AMB. Thus, rapid detection of rs-AMB among clinical isolates will help in proper management of invasive *C. kefyr* infections.

KEYWORDS *Candida kefyr*, *ERG2*, nonsynonymous mutations, reduced susceptibility, amphotericin B

Editor Alexandre Alanio, Institut Pasteur

Copyright © 2023 Asadzadeh et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Suhail Ahmad, suhail.ahmad@ku.edu.kw.

The authors declare no conflict of interest.

Received 16 May 2023

Accepted 1 June 2023

Published 26 June 2023

The incidence of invasive fungal infections (IFIs) is rising globally due to increasing populations of immunocompromised or immunosuppressed individuals and other older hospitalized patients with multiple debilitating comorbidities (1–3). The IFIs occur more frequently among at-risk patients during their stay in intensive care units (ICUs) and are associated with high mortality rates (4–6). The spectrum of *Candida* and other yeast species causing IFIs is changing due to increasing use of antifungal prophylaxis (4, 7). Emergence of drug-resistant and multidrug-resistant (MDR) *Candida* and other yeast spp. is another matter of great concern due to the limited antifungal armamentarium available to treat invasive infections (6, 8–10). Recent reports have documented MDR among clinical isolates of *Candida glabrata* (11–13), *Candida auris* (14–16), *Candida haemulonii* complex members (17, 18), *Candida lusitanae* (19), and *Candida kefyi* (20, 21).

Invasive rare yeast infections are difficult to treat due to their intrinsic or acquired resistance to one or more antifungal drugs, and clinical breakpoints are mostly unavailable (6, 22). *Candida kefyi* (*Kluyveromyces marxianus*) is a thermotolerant ascomycetous yeast that is isolated from diverse habitats (e.g., kefir grain, raw milk, fermented dairy products, sugar industry sewage, and plant material) and is also widely used in food and industrial biotechnology applications (23–25). *Candida kefyi* is now recognized as an emerging fungal pathogen among ICU patients, as infections due to this yeast are increasingly being reported in recent years in immunocompromised individuals particularly among patients with hematological malignancies (20, 22, 26–33). *C. kefyi* infections have been shown to occur more frequently during summer months among patients with hematologic malignancies (26). This phenomenon may be attributed to the consumption of dairy products containing overgrowth of *C. kefyi* as a result of lack of proper refrigeration during summertime. Indeed, consumption of dairy products (yogurt) containing *C. kefyi* has been shown recently by whole-genome sequencing studies as the most likely source of disseminated infection in an immunocompromised patient with mucositis during induction chemotherapy of acute myeloid leukemia (29). *C. kefyi* bloodstream infections are associated with higher mortality rates than *C. albicans* infections among ICU patients (2). Thus, proper patient management requires rapid diagnosis and accurate antifungal susceptibility testing (AFST) of clinical *C. kefyi* isolates. Recent studies have shown that clinical *C. kefyi* isolates exhibit reduced susceptibility to antifungals, particularly amphotericin B (20, 21, 28, 33). The molecular basis of reduced susceptibility to amphotericin B (rs-AMB) among *Candida* and yeast species, including *C. kefyi*, is poorly defined. A prevalence of <1% has recently been reported for *C. kefyi* among clinical yeast isolates, and some *C. kefyi* isolates exhibited rs-AMB in a previous study from Kuwait (20). Here, we describe genetic alterations in major genes involved in ergosterol biosynthesis and their association with total cell sterols among clinical *C. kefyi*, including rs-AMB isolates.

RESULTS

Clinical *C. kefyi* isolates and their susceptibility to antifungal drugs. A total of 81 clinical *C. kefyi* isolates obtained from 74 patients (see Table S1 in the supplemental material) and identified by phenotypic and molecular methods were studied to decipher the molecular mechanisms conferring rs-AMB. The AFST data for AMB, fluconazole, voriconazole, and micafungin obtained by Etest are shown in Table 1. Based on epidemiological cutoff values described previously (34), 73 *C. kefyi* isolates were wild type (WT; minimum inhibitory concentration, MIC \leq 1 μ g/mL) while 8 isolates were non-WT (MIC $>$ 1 μ g/mL) for AMB (rs-AMB). On the contrary, based on the epidemiological cutoff values described previously for fluconazole, voriconazole, and micafungin (34, 35), only 2, 1, and 1 isolate were non-WT, while the remaining 79, 80, and 80 isolates were WT for fluconazole, voriconazole, and micafungin, respectively. One isolate (Kw2153/18) was non-WT for all four drugs, while another isolate (Kw135/15) was non-WT for AMB and fluconazole. When AFST was performed by using the Sensititre YeastOne (SYO) on 12 selected isolates, 10 isolates yielded concordant results for AMB, while two isolates WT by Etest scored as non-WT for AMB (rs-AMB). Surprisingly, isolate

TABLE 1 MIC values of 81 *C. kefyr* isolates for amphotericin B, fluconazole, voriconazole, and micafungin by Etest

Antifungal drug	No. of isolates with MIC ($\mu\text{g/mL}$) of ^a :																					
	≤ 0.01	0.02	0.03	0.06	0.09	0.13	0.19	0.25	0.38	0.5	0.75	1	2	3	4	8	16	32	64	128	>256	
Amphotericin B			3	6	1	2	8	12	<u>21</u>	11	6	3			1			7				
Fluconazole			1	1	3	3	<u>19</u>	13	10	17	7	5		1								1
Voriconazole	<u>50</u>	25	5															1				
Micafungin	3	22	15	<u>30</u>	7	2	1					1										

^aThe modal minimum inhibitory concentration (MIC) values are underlined. MIC values indicative of non-WT pattern for each antifungal drug are shown in boldface.

Kw2153/18, non-WT for AMB, fluconazole, voriconazole, and micafungin by Etest, was WT for fluconazole, voriconazole, and micafungin by SYO. Repeat testing of isolates with discrepant results yielded the same patterns by both Etest and SYO. The remaining isolates yielded concordant results for fluconazole, voriconazole, and micafungin by SYO (Table 2).

Analysis of *ERG* gene sequences and ergosterol content. The complete genome sequence data are available for 4 different *C. kefyr* strains, while susceptibility data are available for only 2 of these 4 strains. The encoded ERG2 protein (sterol C8-C7 isomerase) sequences are identical for *C. kefyr* ATCC 26548 WT for AMB (36) (GenBank accession number [AP012218](#)), *C. kefyr* 100656-19 WT for AMB (29) (GenBank accession number [PRJEB33886](#)), *C. kefyr* DMKU3-1042 (GenBank accession number [NC_036030](#)) and *C. kefyr* FIM1 (GenBank accession number [CP015059](#)). The DNA and encoded protein sequence data from *C. kefyr* ATCC 26548 were used as reference in this study. Compared to the reference sequence, several nonsynonymous mutations and one deletion frameshift mutation were detected among clinical *C. kefyr* isolates tested here. These included an Ala-to-Ser change at position 113 (A113S) mutation in 3 isolates WT for AMB as well as in *C. kefyr* ATCC 28838, which was used as a reference for sterol analyses in this study. Among 6 rs-AMB isolates, a nonsynonymous mutation (G90C, M93I, E105K, L107S, G121C, or H155R) was detected in 1 isolate each (Table 2). A G616A transition together with deletion of nucleotide T at position 617 ($\Delta\text{nt } 617\text{t}$), resulting in a frameshift at codon 206 and premature termination of the protein at codon 208 (KTV206ST*), was detected in 1 rs-AMB (Kw1661/19) isolate (Table 2). One rs-AMB isolate (Kw2153/18) and the remaining 70 isolates WT for AMB by Etest contained the wild-type sequence for *ERG2*; this also supported the use of the *C. kefyr* ATCC 26548 sequence as reference. A few synonymous mutations, including heterozygosity, were also detected among some isolates. Nonsynonymous mutations G90C, M93I, E105K, L107S, G121C, and H155R likely resulted in complete loss of ERG2

TABLE 2 Susceptibility to antifungal drugs by Etest and Sensititre YeastOne (SYO) methods, mutations in *ERG2*, *ERG3*, *ERG6*, and *ERG11* genes, and ergosterol contents^a

Isolate no.	Source	Etest MIC ^b ($\mu\text{g/mL}$)				SYO MIC ^b ($\mu\text{g/mL}$)				Mutation(s) identified in ^c :				% ergosterol ^d
		AMB	FLU	VOR	MFG	AMB	FLU	VOR	MFG	<i>ERG2</i>	<i>ERG3</i>	<i>ERG6</i>	<i>ERG11</i>	
ATCC 28838	Human	0.25	0.09	≤ 0.01	0.03	1	0.25	≤ 0.01	0.03	A113S	WT	WT	WT	70.5 \pm 7.4
Kw 1672/11	Urine	0.25	0.19	0.01	0.03	2	0.5	0.02	0.06	WT	WT	WT	WT	85.2 \pm 0.9
Kw197/13	Sputum	0.19	0.5	≤ 0.01	0.03	0.5	0.25	≤ 0.01	0.03	A113S	WT	D168G	WT	64.0 \pm 2.3
Kw 3153/14	Urine	0.13	0.38	≤ 0.01	0.05	0.5	≤ 0.12	≤ 0.01	0.02	WT	WT	D4E + K163Q	WT	85.9 \pm 2.3
Kw 3267/17	Blood	0.19	0.5	≤ 0.01	0.05	2	0.5	≤ 0.01	0.06	A113S	WT	K163Q	WT	72.8 \pm 5.7
Kw 3352/11	Urine	32	0.03	≤ 0.01	0.06	8	0.25	≤ 0.01	0.12	G121C	N313S	WT	WT	0
Kw135/15	Urine	32	3	0.03	0.09	8	4	0.03	0.25	E105K	WT	WT	K151R + Y227D	0
Kw 2327/17	BAL	32	0.5	0.02	0.09	4	≤ 0.12	≤ 0.01	0.06	M93I	WT	WT	WT	0
Kw 1075/18	Ear swab	32	0.5	0.03	0.09	4	1	0.03	0.25	H155R	WT	WT	WT	0
Kw 2153/18	ETT	4	256	32	1	2	0.5	0.03	0.06	WT	S218P	F363L	WT	0
Kw 1661/19	Sputum	32	0.75	0.03	0.06	8	0.5	0.02	0.25	$\Delta\text{nt } 617\text{t}$	WT	WT	WT	77.9 \pm 0.3
Kw196-11/20	BAL	32	0.13	≤ 0.01	0.13	2	0.5	0.03	0.06	L107S	WT	WT	K189R	0
Kw20-12/20	Urine	32	0.25	0.02	0.19	8	0.5	0.02	0.25	G90C	WT	F363L	WT	0

^aBAL, bronchoalveolar lavage; ETT, endotracheal secretion; AMB, amphotericin B; FLU, fluconazole; VOR, voriconazole; MFG, micafungin.

^bThe MIC values indicative of the non-WT pattern for each antifungal drug are shown in bold.

^cThe *ERG* gene sequences from *C. kefyr* ATCC 26548 were used as reference.

^dErgosterol values (percentages of total sterols) are means \pm standard deviations for three replicates.

function, as ergosterol was totally absent among all 6 rs-AMB isolates with these mutations (Table 2). Furthermore, ergosta-type sterols accumulated, indicating the loss of ERG2 protein function in the isolates with these mutations (described in more detail below). No ergosterol was detected in rs-AMB isolate Kw2153/18 with WT sequence for the ERG2 protein, while nearly normal levels were found in rs-AMB isolate Kw1661/19 with premature termination of the ERG2 protein (Table 2). High levels of ergosterol were present among reference *C. kefyr* ATCC 28838 and 4 selected isolates WT for AMB by Etest (Table 2).

Compared to the WT sequence of ERG6 (C-24 sterol methyltransferase) protein from *C. kefyr* ATCC 26548 (GenBank accession number [AP012215](#)), one or more nonsynonymous mutations were found among 11 of 81 isolates. These included an F363L mutation in 3 isolates (1 WT for AMB and 2 rs-AMB), K163Q in 2 isolates WT for AMB, D168G in 1 isolate WT for AMB, D4E plus K163Q mutations in 4 isolates WT for AMB, and D4E plus K163R mutations in 1 isolate WT for AMB by Etest. However, 3 selected isolates (Kw197/13, Kw3153/14, and Kw3267/17) WT for AMB by Etest but containing D168G or D4E plus K163Q or K163Q mutations contained ergosterol levels nearly similar to the reference *C. kefyr* ATCC 28838 and another isolate (Kw1672/11) WT for AMB by Etest and ERG6 protein sequence (Table 2). A few synonymous mutations, including heterozygosity, were also detected in *ERG6* among some isolates.

Since rs-AMB isolate Kw2153/18 with WT ERG2 protein (a role for the F363L mutation in ERG6 in rs-AMB was ruled out, as this mutation was also present in 1 isolate WT for AMB) completely lacked ergosterol and since ERG3 and ERG11 genes could also be involved in conferring rs-AMB in *Candida* spp. (37–40), these two gene sequences were also analyzed from all 8 rs-AMB and 4 selected isolates WT for AMB by Etest. Compared to the WT sequence of ERG3 (sterol $\Delta^{5,6}$ desaturase) protein from *C. kefyr* ATCC 26548 (GenBank accession number [AP012214](#)), two nonsynonymous mutations were detected, N313S in rs-AMB isolate (Kw3352/11) and S218P in rs-AMB isolate Kw2153/18, and both isolates lacked ergosterol (Table 2). Compared to the WT sequence of ERG11 (lanosterol 14 α -demethylase) protein from *C. kefyr* ATCC 26548 (GenBank accession number [KF964546](#)), three nonsynonymous mutations were detected, both in rs-AMB isolates. Two mutations (K151R and Y227D) were found in isolate Kw135/15, non-WT for fluconazole and AMB, and a K189R mutation in Kw196-11/20, WT for fluconazole but non-WT for AMB. In order to further elucidate the role of these mutations (K189R and K151R plus Y227D) in reduced susceptibility to fluconazole and AMB, the *ERG11* sequence was determined from an additional 20 (all WT for fluconazole) isolates. The data showed that 5 of 20 isolates also contained the K189R mutation in *ERG11*, while K151R or Y227D or any other nonsynonymous mutation was not detected. A few synonymous mutations, including heterozygosity, were also detected among some isolates in *ERG3* as well as in *ERG11*.

No mutation was detected in hot spot 1 (HS-1) or HS-2 of *FKS1* in any of the 12 *C. kefyr* isolates, including the isolate non-WT for micafungin, as also reported previously (20). All nonsynonymous mutations in *ERG* genes were double confirmed by extraction of DNA again from *C. kefyr* isolates and PCR sequencing of the respective loci.

Sterol compositions in *C. kefyr* isolates. Ergosterol comprised 64% to 90% of the total cell sterol in reference strain *C. kefyr* ATCC 28838 and 4 selected clinical *C. kefyr* isolates WT for AMB by Etest (Table 3). Interestingly, reference *C. kefyr* ATCC 28838, Kw197/13, and Kw3267/17 contained lower (64.0% to 72.8%) ergosterol levels and 12.4% to 16.1% ergosta-5,7-dienol levels, and all these three strains contained a nonsynonymous mutation (A113S) in *ERG2* (Table 3). Of 8 rs-AMB isolates, only isolate Kw1661/19 contained ergosterol levels similar to isolates WT for AMB, while the remaining 7 isolates completely lacked ergosterol (Table 3). Of the latter 7 isolates, 6 isolates accumulated ergosta-type sterols [ergosta-8-enol; ergosta-8,22-dienol; ergosta-5,8,22-trienol; ergosta-8,24(28)-dienol or fecosterol and ergosta-5,8,24(28)-trienol], indicating loss of ERG2 protein function, and all these 6 isolates contained nonsynonymous mutations in *ERG2* (Tables 2 and 3). Furthermore, the remaining rs-AMB isolate (Kw2153/18) lacking ergosterol accumulated ergosta-7,22-dienol, episterol [ergosta-7,24(28)-dienol] and ergosta-8,22-dienol, indicating loss of ERG3 protein function. Indeed, this Kw2153/18 isolate contained a novel S218P nonsynonymous

TABLE 3 Total *C. kefyr* cell sterol composition in 4 isolates WT for amphotericin B and 8 isolates with rs-AMB

Type of sterol detected	% of different sterols present in total cell sterols ^a of <i>C. kefyr</i> isolate no.:															
	ATCC 28838	Kw1672/11	Kw197/13	Kw3153/14	Kw3267/17	Kw3352/11	Kw135/15	Kw2327/17	Kw1075/18	Kw2153/18	Kw1661/19	Kw196-11/20	Kw20-12/20			
Ergosta-5,8,22,24(28)-tetraenol	1.0 ± 0.5	2.2 ± 0.7	1.4 ± 0.5	2.4 ± 1.6	0.3 ± 0.2	2.1 ± 0.6	2.0 ± 0.5	1.9 ± 0.4	2.1 ± 0.8	1.4 ± 0.4	0.9 ± 0.6	1.0 ± 0.3				
Ergosta-5,8,22-trienol	0.4 ± 0.3	0.5 ± 0.1	0.7 ± 0.2	1.1 ± 0.5	0.2 ± 0.1	33.4 ± 4.4	28.9 ± 4.1	24.4 ± 2.6	41.4 ± 6.0	0.7 ± 0.3	37.0 ± 1.5	35.4 ± 3.1				
Ergosta-8,22-dienol	1.3 ± 0.8	2.2 ± 0.2	8.5 ± 2.6	5.6 ± 2.8	2.8 ± 1.7	25.9 ± 4.6	21.8 ± 2.8	21.1 ± 2.3	24.6 ± 3.1	12.0 ± 1.1	4.5 ± 1.6	19.7 ± 3.6				
Zymosterol (Cholesta-8,24-dienol)	70.5 ± 7.4	85.2 ± 0.9	64.0 ± 2.3	85.9 ± 2.3	72.8 ± 5.7	10.3 ± 2.6	9.6 ± 2.2	8.4 ± 0.9	12.6 ± 1.0	10.2 ± 2.2	77.9 ± 0.3	8.8 ± 1.9				
Ergosta-5,8,24(28)-trienol										1.7 ± 0.4						
Ergosta-8,22,24(28)-trienol										67.9 ± 2.3						
Ergosta-7,22-dienol	1.5 ± 0.5	2.3 ± 0.2	0.8 ± 0.6	0.8 ± 0.5						0.5 ± 0.3						
Ergosta-5,8-dienol						0.4 ± 0.3	0.9 ± 0.4	1.4 ± 0.3	0.5 ± 0.3							1.0 ± 0.4
Fecosterol [Ergosta-8,24(28)-dienol]	4.5 ± 2.4	1.3 ± 0.6	3.8 ± 0.4	1.1 ± 0.3	2.0 ± 1.0	9.1 ± 2.7	14.6 ± 3.3	26.4 ± 1.9	5.5 ± 0.4	1.8 ± 1.0	1.0 ± 0.5	10.8 ± 5.2	9.8 ± 2.9			
Ergosta-5,7,24(28)-trienol	1.2 ± 0.4	1.0 ± 0.1	1.3 ± 0.7	2.0 ± 1.3							1.2 ± 0.5					
Ergosta-8-enol						14.9 ± 4.1	20.0 ± 3.7	12.7 ± 3.9	11.7 ± 1.0	0.8 ± 0.3	10.4 ± 1.0	22.5 ± 0.7				
Ergosta-5,7-dienol	12.4 ± 4.4	2.3 ± 0.9	14.3 ± 1.3	0.3 ± 0.0	16.1 ± 3.2											
Episterol [Ergosta-7,24(28)-dienol]	2.3 ± 0.5	0.4 ± 0.2	3.6 ± 1.1	1.0 ± 0.6	1.6 ± 0.8					13.4 ± 1.4	1.3 ± 0.4					
Ergosta-7-enol										1.7 ± 0.8						
Lanosterol	4.0 ± 0.7	2.2 ± 1.2	0.5 ± 0.3	1.0 ± 0.7	0.8 ± 0.4	1.3 ± 0.7	1.6 ± 0.2	0.3 ± 0.1	0.1 ± 0.0	0.4 ± 0.2	0.7 ± 0.3	0.3 ± 0.1	0.5 ± 0.2			
4,4-Dimethyl cholesta-8,24-dienol	0.8 ± 0.9	0.3 ± 0.3	0.9 ± 0.5	1.2 ± 0.9	0.3 ± 0.0	0.4 ± 0.3	0.3 ± 0.1	0.8 ± 0.2	0.4 ± 0.2	0.4 ± 0.1	0.3 ± 0.1	0.1 ± 0.1	0.2 ± 0.1			
Unknown sterol						2.3 ± 1.4	0.3 ± 0.2	2.7 ± 1.1	0.2 ± 0.2			0.8 ± 1.2	1.0 ± 0.5			
Eburicol	0.2 ± 0.2	0.2 ± 0.2	0.2 ± 0.1	0.4 ± 0.4	0.4 ± 0.3	0.4 ± 0.3	0.2 ± 0.2	0.1 ± 0.1	0.8 ± 0.6		0.2 ± 0.2					

^a*C. kefyr* ATCC 28838 was used as a reference strain for determining total cell sterol composition among clinical *C. kefyr* isolates. Mean percentage sterol values are from 3 replicates (with standard deviations). Values of >5% total cell sterol are shown in bold.

mutation in *ERG3* which was absent in other rs-AMB isolates or other isolates WT for AMB by Etest. Although another isolate, Kw3352/11, also contained another N313S nonsynonymous mutation in *ERG3*, sterol profiles did not indicate loss of *ERG3* protein function in this isolate. Interestingly, none of the isolates accumulated lanosterol, including Kw135/15 (with K151R plus Y227D mutations in *ERG11*), non-WT for fluconazole (Table 3).

DISCUSSION

The high mortality rates associated with invasive *Candida* and other yeast infections are mainly due to availability of a limited number of effective antifungal drugs and emergence of drug-resistant and multidrug-resistant *Candida* and other yeast species (2, 4, 6, 9, 41). Although resistance to AMB is rarely observed in clinical *C. albicans* isolates or other frequently encountered *Candida* species (such as *C. parapsilosis* and *C. tropicalis*), it is increasingly being reported in rare yeast species (such as *C. lusitanae*, *C. haemulonii*, and *C. kefyr*) and is a matter of major concern with *C. glabrata* and multidrug-resistant *C. auris* for effective clinical treatment (11, 16, 39, 40, 42–46). Previous studies carried out on clinical rs-AMB isolates and *in vitro*-generated strains have identified *ERG1*, *ERG2*, *ERG3*, *ERG6*, and/or *ERG11* encoded proteins involved in ergosterol biosynthesis as major targets conferring rs-AMB in some *Candida* spp. (11, 16, 37, 38, 40, 47–49).

In this study, AFST of 81 *C. kefyr* isolates by Etest identified 8 rs-AMB and 73 isolates WT for AMB. However, AFST results by SYO were concordant for only 10 of 12 selected *C. kefyr* isolates. Although SYO correctly identified 8 of 8 rs-AMB isolates, 2 of 4 isolates WT for AMB by Etest scored as rs-AMB (categorical agreement for 10 of 12 or 83.3% of the isolates). Both isolates (Kw197/13 and Kw3267/17) with discordant results contained ergosterol as their major cell sterol, indicating susceptibility to AMB. Concordance between different AFST methods for AMB among yeast species is not perfect, especially the commercial systems (50–52). Previous studies have also shown discordant AFST results for *C. albicans* isolates with defects in *ERG3* (40, 53). The essential agreement (± 2 2-fold dilutions) between Etest and SYO was even poorer (7 of 12, or 58.3%). In a recent study on *C. auris* isolates, an essential agreement (± 1 dilution) of only 29% and a categorical agreement of 11% were obtained between SYO and the reference methodology by the Clinical and Laboratory Standards Institute for AMB (54). Only use of a higher wild-type upper limit for the MIC or 50% or 75% growth inhibition during SYO testing improved categorical agreement to $\geq 97\%$ (54).

The identical *ERG2*-encoded protein sequence from 4 *C. kefyr* strains (ATCC 26548, 100656-19, DMKU3-1042, and FIM1) were used as reference in this study. A total of 70 *C. kefyr* isolates from Kuwait that were WT for AMB by Etest also contained the wild-type sequence for the *ERG2*-encoded protein, which further supports the use of the *C. kefyr* ATCC 26548 sequence as reference. The results of *ERG2* sequencing and sterol analyses were remarkable for 7 of 8 rs-AMB isolates. Six rs-AMB isolates contained a nonsynonymous mutation (G90C, M93I, E105K, L107S, G121C, or H155R), completely lacked ergosterol, and accumulated ergosta-8-enol, ergosta-8,22-dienol, ergosta-5,8,22-trienol, and ergosta-8,24(28)-dienol (fecosterol), clearly showing a block of *ERG2* activity in the ergosterol biosynthetic pathway (46). Nonsynonymous mutations in *ERG2* causing loss of ergosterol and accumulation of ergosta-type sterols have also previously been linked to loss of *ERG2* protein function and rs-AMB in *C. glabrata* (11, 47). Although the above six nonsynonymous mutations were absent in 73 isolates WT for AMB, 3 WT isolates as well as *C. kefyr* isolate (ATCC 28838) used as reference for sterol analyses in this study contained another (A113S) nonsynonymous mutation in *ERG2*. Although all 4 isolates WT for AMB and *C. kefyr* ATCC 28838 analyzed for total cell sterols contained ergosterol as the major cell sterol, as expected, 2 of 4 WT isolates with A113S mutation and the reference *C. kefyr* ATCC 28838 contained slightly lower levels of ergosterol and also accumulated ergosta-5,7-dienol. Interestingly, A113 is also conserved among different yeast species except *C. auris* (see Fig. S1) which, similar to *C. kefyr* with the A113S mutation, also accumulated $>5\%$ amounts of ergosta-5,7-dienol (16).

One rs-AMB isolate (Kw1661/19) contained a G-to-A transition at nucleotide 616 and deletion of one nucleotide (617T) which caused a frameshift and resulted in

premature termination of the *ERG2* transcript at codon 308, while another rs-AMB isolate (Kw2153/18) contained wild-type sequence for *ERG2*. Although isolate Kw1661/19 contained ergosterol, its levels were similar to WT isolates (ATCC 28838, Kw197/13, and Kw3267/17) containing the A113S nonsynonymous mutation in *ERG2*, and it also accumulated ergosta-5,7-dienol, indicating that the truncated C-terminal end in *ERG2* in this isolate was perhaps causing the same effects as the A113S mutation in some other isolates. It is not clear at present how the A113S mutation or truncation of the C-terminal end in *ERG2* could result in accumulation of ergosta-5,7-dienol, which usually occurs in isolates with reduced activity of the *ERG5*-encoded protein. *ERG5* was not sequenced in this study. Interestingly, nonsynonymous mutations G90C, M93I, E105K, L107S, and G121C map within the highly conserved region of *ERG2* protein, comprising codons 84 to 132 (*C. kefyri* codon numbering) among different yeast species (Fig. S1). This extended region includes G118, T120, and G121 (G119, T121, and G122 in *C. glabrata* codon numbering) that are mutated in rs-AMB *C. glabrata* isolates (11, 47).

Although several nonsynonymous mutations were detected in *ERG6* either singly or in combination, they were found in some rs-AMB as well as in some isolates WT for AMB, and the sterol profiles of the 12 selected isolates, including isolates WT for AMB with an *ERG6* mutation(s), did not show loss of *ERG6* protein function, as they did not accumulate cholesta-type sterols. This is contrary to the data obtained with rs-AMB *C. glabrata* and *C. auris*. The rs-AMB in *C. glabrata* is mainly associated with loss of *ERG6* protein function (11, 48, 55). Loss of *ERG6* protein not only confers rs-AMB but also affects cell wall integrity and calcineurin signaling in *C. glabrata* (56). The only known molecular mechanism of rs-AMB in *C. auris* confirmed so far also involves loss of *ERG6* protein function (16, 57).

Sterol analyses of the 12 selected *C. kefyri* isolates indicated loss of *ERG3* protein function in rs-AMB isolate Kw2153/18, as it accumulated ergosta-7,22-dienol, ergosta-8,22-dienol, and episterol. Indeed, PCR sequencing of *ERG3* from 12 selected isolates identified a novel (S218P) nonsynonymous mutation in isolate Kw2153/18, which was absent in the remaining 12 isolates. Although isolate Kw3352/11 also contained another (N313S) nonsynonymous mutation in *ERG3*, it likely represented a mere polymorphism, as this isolate contained C₅ desaturated sterols, indicating that the *ERG3* protein is active. Furthermore, the role of N313S mutation in *ERG3* in rs-AMB is also unlikely, as isolate Kw3352/11 contained a G121C mutation in *ERG2* and the sterol profiles indicated loss of *ERG2* rather than *ERG3* protein function (Tables 2 and 3). The G121 (G122 in *C. glabrata*) is also mutated (Fig. S1) in one rs-AMB *C. glabrata* isolate described previously (11). The results of *ERG11* sequencing were unremarkable except for one isolate (Kw135/15) non-WT for fluconazole. Although K151 is conserved across several *Candida* spp. and Y227 is also located within another highly conserved region of *ERG11* (Fig. S2), the effects of K151R and Y227D nonsynonymous mutations in isolate Kw135/15 on *ERG11* activity remain unclear due to lack of lanosterol accumulation. The nonsynonymous mutation K189R detected in *ERG11* in rs-AMB isolate Kw196-11/20 is a polymorphism not connected with antifungal resistance, as this alteration was also detected in an additional 5 of 20 *C. kefyri* isolates WT for all four antifungal drugs. Furthermore, R189 is also found in *ERG11* from *C. tropicalis* and *C. auris* (Fig. S2). Taken together, the molecular basis of reduced susceptibility to fluconazole in isolates Kw135/15 and Kw2153/18 remains unclear.

The molecular basis of rs-AMB in isolate Kw1661/19 remains unknown. It has recently been suggested that, similar to molecular genetic analyses of *ERG* genes, analysis of total cell sterols among clinical yeast isolates can also be used to predict reduced susceptibility to triazoles and polyene antifungal drugs (58). Although isolate Kw1661/19 was scored as rs-AMB by Etest and SYO, our data showed that both of the above (*ERG* genes and sterol analyses) approaches are imperfect. Isolate Kw1661/18 contained a deletion frameshift mutation in *ERG2*, which is indicative of loss of function and hence rs-AMB, but the sterol profiles did not show loss of *ERG2* protein function. On the contrary, presence of ergosterol as the major (77.9%) constituent of total cell sterol is indicative of the WT pattern for AMB susceptibility even though *in vitro* AFST results indicated rs-AMB. It is probable that rs-AMB

in isolate Kw1661/19 is due to involvement of ergosterol-independent (such as efflux pump) resistance mechanisms.

Our study has a few limitations. (i) The definitive role of *ERG2* mutations in conferring rs-AMB in *C. kefyr* was not confirmed by gene replacement studies. (ii) *ERG3*, *ERG11* gene sequencing, and sterol analyses were not performed on all *C. kefyr* isolates. (iii) Other *ERG* genes, such as *ERG4* and *ERG5*, were not analyzed. (iv) Information on treatment of patients yielding *C. kefyr* isolates with antifungal drugs was not available.

In conclusion, 8 of 74 (10.8%) patients yielded rs-AMB *C. kefyr* isolates in Kuwait. Six rs-AMB isolates contained nonsynonymous mutations in *ERG2*, and their total cell sterol contents were consistent with loss of *ERG2*-encoded protein function. These specific mutations were also absent in 73 isolates WT for AMB. One rs-AMB isolate contained a nonsynonymous mutation in *ERG3* with concomitant total cell sterol profiles, while the molecular basis of rs-AMB in another isolate remained unknown even though it contained a frameshift mutation in *ERG2* near the C-terminal end; this change was not associated with corresponding changes in total cell sterol profiles. Our data showed that *ERG2* is a major target conferring rs-AMB in clinical *C. kefyr* isolates in Kuwait.

MATERIALS AND METHODS

Clinical *C. kefyr* isolates, culture conditions, and identification. A total of 81 *C. kefyr* isolates recovered from various clinical specimens (Table S1) obtained from 74 patients admitted in different hospitals across Kuwait and obtained during 2011 to 2020 were used. *C. kefyr* ATCC 28838 and *C. kefyr* ATCC 26548 (CBS 6556), susceptible to fluconazole, voriconazole, micafungin, and amphotericin B (20, 36), were used as reference strains. The clinical specimens yielding *C. kefyr* were collected from adult patients in different hospitals after obtaining informed verbal consent only as part of routine patient care and diagnostic workup for cultivation, identification, and antifungal drug susceptibility testing (AFST) of fungal pathogens.

The specimens were cultured in Bactec Plus blood culture bottles (Beckton Dickinson, Sparks, MD, USA) and/or Sabouraud dextrose agar (Difco) plates supplemented with chloramphenicol (50 $\mu\text{g}/\text{mL}$) as described previously (20, 59). All isolates were identified to the species level by using the Vitek 2 yeast identification system (bioMérieux, Marcy-l'Étoile, France). DNA from all isolates was extracted by using a commercial kit (Gentra Puregene yeast DNA extraction kit, Qiagen, Hilden, Germany) or by the rapid boiling method using Chelex-100, as described previously (60). Molecular identity of each isolate was established by PCR amplification of internal transcribed spacer (ITS) region of rDNA by using *C. kefyr*-specific CKEF (5'-GCTCGTCTCTCCAGTGGACATA-3') and CKER (5'-ACTCACTACCAACCCAAAGGT-3') primers, as described previously (20). PCR sequencing of rDNA was also done for 30 selected *C. kefyr* isolates, including all drug-resistant isolates, by using pan-fungal primers, as described previously (61).

Antifungal drug susceptibility testing. The AFST was initially performed for all *C. kefyr* isolates against AMB, fluconazole, voriconazole, and micafungin by Etest (bioMérieux SA, Marcy-l'Étoile, France), following the manufacturer's instructions. Reference strains of *C. parapsilosis* (ATCC 22019) and *C. albicans* (ATCC 90028) were also used for quality control. Since there are no susceptibility breakpoints available for *C. kefyr*, epidemiological cutoff values were used for interpreting the MIC values for AMB, fluconazole, voriconazole, and micafungin. Isolates with MICs of ≤ 1.0 $\mu\text{g}/\text{mL}$, ≤ 1.0 $\mu\text{g}/\text{mL}$, ≤ 0.03 $\mu\text{g}/\text{mL}$, and ≤ 0.5 $\mu\text{g}/\text{mL}$ were considered WT, while isolates with MICs of > 1.0 $\mu\text{g}/\text{mL}$, > 1.0 $\mu\text{g}/\text{mL}$, > 0.03 $\mu\text{g}/\text{mL}$, and > 0.5 $\mu\text{g}/\text{mL}$ were considered non-WT for AMB, fluconazole, voriconazole, and micafungin, respectively (34, 35). All 8 rs-AMB isolates and 4 selected isolates wild-type for AMB were also tested by using the SYO broth dilution colorimetric method by following the manufacturer's instructions, as described previously (35).

Sequencing of *ERG* genes participating in ergosterol synthesis. The complete coding sequences of *ERG2* and *ERG6* genes, frequently implicated in rs-AMB among *Candida* spp. (11, 16, 47, 48), were obtained for all *C. kefyr* isolates by PCR amplification from genomic DNA, followed by bidirectional amplicon sequencing by using gene-specific primers. The *ERG2* gene was amplified by using CkefERG2F (5'-GGATTTAGG GGAATTAAGTAG-3') and CkefERG2R (5'-CTACCGTCAGTACACAAGTGTA-3') primers and amplification reaction and cycling conditions described previously (62). A PCR product purification kit (Qiagen, Hilden, Germany) was used according to kit instructions to purify the amplicons, and both strands were sequenced by using forward (CkefERG2F or CkefERG2FS, 5'-GAAATTAAGTAGTTCTACTCT-3') or reverse (CkefERG2RS1, 5'-ACCGTCAGTACACAAGTGATAT-3' or CkefERG2RS2, 5'-AACTTCAGGAAGTAGATTGTGT-3') primers together with a BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Austin, TX, USA) and an ABI 3130xl Genetic Analyzer according to the manufacturer's instructions (Applied Biosystems), as described previously (11, 20). The complete *ERG2* sequences of ~ 846 bp were assembled and compared with the corresponding sequences from reference strain *C. kefyr* ATCC 26548 by using the Clustal omega program (<https://www.ebi.ac.uk/Tools/msa/clustalo/>).

The *ERG6* coding and the flanking noncoding regions were amplified and sequenced as two overlapping fragments. The N-terminal fragment was amplified by using CkefERG6F1 (5'-AATTTGCGCAGTAAGAGAGAGA-3') and CkefERG6R1 (5'-GACTGGGTACATCTTTGGAATA-3') primers, while the C-terminal fragment was amplified by using CkefERG6F2 (5'-GAAATTGAACTAGGTGACGGTA-3') and CkefERG6R2 (5'-GTTTGAGACCT

TCCGCTCCACT-3') primers and PCR amplification reaction and cycling conditions described previously (62). The amplicons were purified as described above, and both strands were sequenced by using the gene-specific primers and the sequencing protocol described previously (11, 20). The sequencing primers for the N-terminal fragment included forward (CkefERG6FS1, 5'-TGCGCAGTAAGAGAGAGACCA-3') and reverse (CkefERG6RS1, 5'-GACTGGGTACATCTTTGGAATA-3' or CkefERG6RS2, 5'-AGCACAAAGTCGTTCTCCTTGA-3') primers. The C-terminal fragment was sequenced by using forward (CkefERG6F2) and reverse (CkefERG6RS3, 5'-ACCTCCGCTCCACTTTTTCT-3') primers. The complete *ERG6* coding sequences of 1,128 bp were assembled and compared with the corresponding sequences from reference *C. kefyr* ATCC 26548 by using the Clustal omega program.

The *ERG3* and *ERG11* genes were also amplified and sequenced from 12 selected isolates, including all rs-AMB isolates. The *ERG3* gene was amplified and sequenced as two overlapping fragments. The N-terminal fragment was amplified by using CkefERG3F1 (5'-GAAAGAGTGTGTTCTAGCTGA-3') and CkefERG3R1 (5'-CAATGGGAATAGCATTGGGTA-3') primers, while the C-terminal fragment was amplified by using CkefERG3F2 (5'-CAGTCGATGGTTTCATGCAA-3') and CkefERG3R2 (5'-TTACATTGAGACCATCGATA T-3') primers; the amplicons were purified and both strands were sequenced by using the gene-specific primers as described above for *ERG2* and *ERG6*. The sequencing primers for the N-terminal fragment included forward (CkefERG3F or CkefERG3FS1, 5'-CATATTCGGTTGTTGTTGA-3') and reverse (CkefERG3R1 or CkefERG3RS1, 5'-ATGGTTAAACACTGCCTTGTC-3') primers. The C-terminal fragment was sequenced with the same amplification primers (CkefERG3F2 or CkefERG3R2). The complete *ERG3* coding sequences of 1,059 bp were assembled and were compared with the corresponding sequences from reference *C. kefyr* ATCC 26548 by using the Clustal omega program. The complete *ERG11* coding sequence of 1,581 bp was obtained as described previously (20).

Total cell sterol analyses. The total cell sterol content of 12 selected *C. kefyr* isolates was determined as described previously (11, 49). Briefly, the yeast cells were grown for 16 h in morpholinepropa-nesulfonic acid-buffered RPMI medium (pH 7.0) containing 2% glucose. Cells were harvested and nonsaponifiable lipids were extracted, dried in a vacuum centrifuge, and were derivatized with trimethylsilane (TMS). The TMS-derivatized sterols were analyzed by gas chromatography-mass spectrometry (GC-MS). The GC-MS data files were analyzed, and results of three replicates from each sample were used to calculate the mean percentage \pm standard deviation for each sterol (11, 49).

PCR sequencing of hot spot-1 and hot spot-2 of *FKS1*. The hot spot-1 and hot spot-2 regions of the *FKS1* gene, commonly mutated in echinocandin-resistant *Candida* spp. and other yeast species (63), were also amplified and sequenced from all 12 *C. kefyr* isolates by using specific amplification and sequencing primers, as described previously (20).

Ethics statement. The clinical specimens yielding *C. kefyr* isolates analyzed in this study were obtained from hospitalized patients admitted in different hospitals across Kuwait after obtaining informed verbal consent only for culture and antifungal susceptibility testing of fungal pathogens as part of routine diagnostic workup. The isolates were used in the Department of Microbiology, Faculty of Medicine, Kuwait University, for identification of fungal pathogens and their susceptibility to antifungal drugs. The results from deidentified samples are described in this paper without revealing patient identity. The study and the consent procedure were approved by the Health Sciences Center Ethics Committee, Kuwait University (approval number VDR/EC/3691).

Data availability. The DNA sequence data reported in this study have been submitted to GenBank under accession numbers [OQ520304](https://doi.org/10.1093/cid/civ933) to [OQ520311](https://doi.org/10.1093/cid/civ933) and [OQ542694](https://doi.org/10.1093/cid/civ933) to [OQ542744](https://doi.org/10.1093/cid/civ933).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, DOCX file, 0.03 MB.

ACKNOWLEDGMENTS

This study was supported and funded by Kuwait University Research Sector grant MI 02/20. We thank Khalid Alobaid for providing some *C. kefyr* isolates and Bram Spruijtenburg for help with part of the antifungal susceptibility testing.

REFERENCES

- Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. *Sci Transl Med* 4:165rv13. <https://doi.org/10.1126/scitransmed.3004404>.
- Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. 2014. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). *Intensive Care Med* 40:1303–1312. <https://doi.org/10.1007/s00134-014-3408-3>.
- Barchiesi F, Orsetti E, Mazzanti S, Trave F, Salvi A, Nitti C, Manso E. 2017. Candidemia in the elderly: what does it change? *PLoS One* 12:e0176576. <https://doi.org/10.1371/journal.pone.0176576>.
- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 62:e1–e50. <https://doi.org/10.1093/cid/civ933>.
- Rayens E, Norris KA, Cordero JF. 2022. Mortality trends in risk conditions and invasive mycotic disease in the United States, 1999–2018. *Clin Infect Dis* 74:309–318. <https://doi.org/10.1093/cid/ciab336>.
- De Bels D, Maillart E, Van Bambeke F, Redant S, Honoré PM. 2022. Existing and emerging therapies for the treatment of invasive candidiasis and candidemia. *Expert Opin Emerg Drugs* 27:405–416. <https://doi.org/10.1080/14728214.2022.2142207>.
- Lamoth F, Lockhart SR, Berkow EL, Calandra T. 2018. Changes in the epidemiological landscape of invasive candidiasis. *J Antimicrob Chemother* 73:i4–i13. <https://doi.org/10.1093/jac/dkx444>.
- Colombo AL, Guimarães T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, Nouér SA, Nucci M. 2014. Prognostic factors and historical trends in

- the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. *Intensive Care Med* 40:1489–1498. <https://doi.org/10.1007/s00134-014-3400-y>.
9. Wiederhold NP. 2021. Emerging fungal infections: new species, new names, and antifungal resistance. *Clin Chem* 68:83–90. <https://doi.org/10.1093/clinchem/hvab217>.
 10. Ahmad S, Alfouzan W. 2021. *Candida auris*: epidemiology, diagnosis, pathogenesis, antifungal susceptibility and infection control measures to combat the spread of infections in healthcare facilities. *Microorganisms* 9: 807. <https://doi.org/10.3390/microorganisms9040807>.
 11. Ahmad S, Joseph L, Parker JE, Asadzadeh M, Kelly SL, Meis JF, Khan Z. 2019. ERG6 and ERG2 are major targets conferring reduced susceptibility to amphotericin B in clinical *Candida glabrata* isolates in Kuwait. *Antimicrob Agents Chemother* 63:e01900-18. <https://doi.org/10.1128/AAC.01900-18>.
 12. Aldejohann AM, Herz M, Martin R, Walther G, Kurzai O. 2021. Emergence of resistant *Candida glabrata* in Germany. *JAC Antimicrob Resist* 3:dlab122. <https://doi.org/10.1093/jacamr/dlab122>.
 13. Merdan O, Şişman AS, Aksoy SA, Kızıl S, Tüzemen NÜ, Yılmaz E, Ener B. 2022. Investigation of the defective growth pattern and multidrug resistance in a clinical isolate of *Candida glabrata* using whole-genome sequencing and computational biology applications. *Microbiol Spectr* 10:e0077622. <https://doi.org/10.1128/spectrum.00776-22>.
 14. Asadzadeh M, Mokaddas E, Ahmad S, Abdullah AA, de Groot T, Meis JF, Shetty SA. 2022. Molecular characterisation of *Candida auris* isolates from immunocompromised patients in a tertiary-care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins. *Mycoses* 65:331–343. <https://doi.org/10.1111/myc.13419>.
 15. Al-Obaid I, Asadzadeh M, Ahmad S, Alobaid K, Alfouzan W, Bafna R, Emara M, Joseph L. 2022. Fatal breakthrough candidemia in an immunocompromised patient in Kuwait due to *Candida auris* exhibiting reduced susceptibility to echinocandins and carrying a novel mutation in hotspot-1 of FKS1. *J Fungi* 8:267. <https://doi.org/10.3390/jof8030267>.
 16. Rybak JM, Barker KS, Muñoz JF, Parker JE, Ahmad S, Mokaddas E, Abdullah A, Elhagracy RS, Kelly SL, Cuomo CA, Rogers PD. 2022. In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in *Candida auris*. *Clin Microbiol Infect* 28:838–843. <https://doi.org/10.1016/j.cmi.2021.11.024>.
 17. Lima SL, Francisco EC, de Almeida Júnior JN, Santos DWCL, Carlesse F, Queiroz-Telles F, Melo ASA, Colombo AL. 2020. Increasing prevalence of multidrug-resistant *Candida haemulonii* species complex among all yeast cultures collected by a reference laboratory over the past 11 years. *J Fungi* 6:110. <https://doi.org/10.3390/jof6030110>.
 18. Ramos LS, Figueiredo-Carvalho MHG, Silva LN, Siqueira NLM, Lima JC, Oliveira SS, Almeida-Paes R, Zancopé-Oliveira RM, Azevedo FS, Ferreira ALP, Branquinho MH, Santos ALS. 2022. The threat called *Candida haemulonii* species complex in Rio de Janeiro State, Brazil: focus on antifungal resistance and virulence attributes. *J Fungi* 8:574. <https://doi.org/10.3390/jof8060574>.
 19. Asner SA, Giulieri S, Diezi M, Marchetti O, Sanglard D. 2015. Acquired multidrug antifungal resistance in *Candida lusitanae* during therapy. *Antimicrob Agents Chemother* 59:7715–7722. <https://doi.org/10.1128/AAC.02204-15>.
 20. Ahmad S, Khan Z, Al-Sweih N, Alfouzan W, Joseph L, Asadzadeh M. 2020. *Candida kefyr* in Kuwait: prevalence, antifungal drug susceptibility and genotypic heterogeneity. *PLoS One* 15:e0240426. <https://doi.org/10.1371/journal.pone.0240426>.
 21. Stavrou AA, Pérez-Hansen A, Lackner M, Lass-Flörl C, Boekhout T. 2020. Elevated minimum inhibitory concentrations to antifungal drugs prevail in 14 rare species of candidemia-causing *Saccharomycotina* yeasts. *Med Mycol* 58:987–995. <https://doi.org/10.1093/mmy/myaa005>.
 22. Bretagne S, Renaudat C, Desnos-Ollivier M, Sitbon K, Lortholary O, Dromer F, French Mycosis Study Group. 2017. Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002–14). *J Antimicrob Chemother* 72: 1784–1793. <https://doi.org/10.1093/jac/dkx045>.
 23. Karim A, Gerliani N, Aider M. 2020. *Kluyveromyces marxianus*: an emerging yeast cell factory for applications in food and biotechnology. *Int J Food Microbiol* 333:108818. <https://doi.org/10.1016/j.jifoodmicro.2020.108818>.
 24. Moravkova M, Huvarova V, Vlckova H, Kostovova I, Bacova R. 2021. Raw bovine milk as a reservoir of yeast with virulence factors and decreased susceptibility to antifungal agents. *Med Mycol* 59:1032–1040. <https://doi.org/10.1093/mmy/myab036>.
 25. Montini N, Doughty TW, Domenzain I, Fenton DA, Baranov PV, Harrington R, Nielsen J, Siewers V, Morrissey JP. 2022. Identification of a novel gene required for competitive growth at high temperature in the thermotolerant yeast *Kluyveromyces marxianus*. *Microbiology (Reading)* 168:e001148. <https://doi.org/10.1099/mic.0.001148>.
 26. Dufresne SF, Marr KA, Sydnor E, Staab JF, Karp JE, Lu K, Zhang SX, Lavalée C, Perl TM, Neofytos D. 2014. Epidemiology of *Candida kefyr* in patients with hematologic malignancies. *J Clin Microbiol* 52:1830–1837. <https://doi.org/10.1128/JCM.00131-14>.
 27. Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, Kontoyiannis DP. 2015. Uncommon *Candida* species fungemia among cancer patients, Houston, Texas, USA. *Emerg Infect Dis* 21:1942–1950. <https://doi.org/10.3201/eid2111.150404>.
 28. Diba K, Makhdoomi K, Nasri E, Vaezi A, Javidnia J, Gharabagh DJ, Jazani NH, Chavshin AR, Badiee P, Badali H, Fakhim H. 2018. Emerging *Candida* species isolated from renal transplant recipients: species distribution and susceptibility profiles. *Microb Pathog* 125:240–245. <https://doi.org/10.1016/j.micpath.2018.09.026>.
 29. Seth-Smith HMB, Büchler AC, Hinic V, Medinger M, Widmer AF, Egli A. 2020. Bloodstream infection with *Candida kefyr/Kluyveromyces marxianus*: case report and draft genome. *Clin Microbiol Infect* 26:522–524. <https://doi.org/10.1016/j.cmi.2019.11.014>.
 30. Aldejohann AM, Theuersbacher J, Haug L, Lamm OS, Walther G, Kurzai O, Hillenkamp J, Kampik D. 2021. First case of *Kluyveromyces marxianus* (*Candida kefyr*) late onset keratitis after lamellar endothelial corneal graft. *Med Mycol Case Rep* 32:21–24. <https://doi.org/10.1016/j.mmcr.2021.02.001>.
 31. Jyothi L, Reddy NP, Naaz S. 2021. An unusual case of *Candida kefyr* fungemia in an immunocompromised patient. *Cureus* 13:e14138. <https://doi.org/10.7759/cureus.14138>.
 32. Reda NM, Hassan RM, Salem ST, Yousef RHA. 2023. Prevalence and species distribution of *Candida* bloodstream infection in children and adults in two teaching university hospitals in Egypt: first report of *Candida kefyr*. *Infection* 51:389–395. <https://doi.org/10.1007/s15010-022-01888-7>.
 33. Spiliopoulou A, Kolonitsiou F, Vrioni G, Tsoupra S, Lekkou A, Paliogianni F. 2022. Invasive *Candida kefyr* infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: case report and review of the literature. *J Mycol Med* 32:101236. <https://doi.org/10.1016/j.mycmed.2021.101236>.
 34. Espinel-Ingroff A, Sasso M, Turnidge J, Arendrup M, Botterel F, Bourgeois N, Bouteille B, Canton E, Cassaing S, Dannaoui E, Dehais M, Delhaes L, Dupont D, Fekkar A, Fuller J, Garcia-Effron G, Garcia J, Gonzalez GM, Govender NP, Guegan H, Guinea J, Houzé C, Lass-Flörl C, Pelaez T, Forastiero A, Lackner M, Magobo R. 2021. Etest ECVs/ECOFFs for detection of resistance in prevalent and three nonprevalent *Candida* spp. to triazoles and amphotericin B and *Aspergillus* spp. to caspofungin: further assessment of modal variability. *Antimicrob Agents Chemother* 65: e0109321. <https://doi.org/10.1128/AAC.01093-21>.
 35. Espinel-Ingroff A, Alvarez-Fernandez M, Cantón E, Carver PL, Chen SC, Eschenauer G, Getsinger DL, Gonzalez GM, Govender NP, Grancini A, Hanson KE, Kidd SE, Klinker K, Kubin CJ, Kus JV, Lockhart SR, Meletiadi S, Morris AJ, Pelaez T, Quindós G, Rodríguez-Iglesias M, Sánchez-Reus F, Shoham S, Wengenack NL, Borrell Solé N, Echeverría J, Esperalba J, Gómez-G de la Pedrosa E, García García I, Linares MJ, Marco F, Merino P, Pemán J, Pérez Del Molino L, Roselló Mayans E, Rubio Calvo C, Ruiz Pérez de Pipaon M, Yagüe G, García-Effron G, Guinea J, Perlin DS, Sanguinetti M, Shields R, Turnidge J. 2015. Multicenter study of epidemiological cutoff values and detection of resistance in *Candida* spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method. *Antimicrob Agents Chemother* 59:6725–6732. <https://doi.org/10.1128/AAC.01250-15>.
 36. Couzigou C, Gabriel F, Biteau N, Fitton-Ouhabi V, Noël T, Accoceberry I. 2014. Two missense mutations, E123Q and K151E, identified in the ERG11 allele of an azole-resistant isolate of *Candida kefyr* recovered from a stem cell transplant patient for acute myeloid leukemia. *Med Mycol Case Rep* 5:12–15. <https://doi.org/10.1016/j.mmcr.2014.04.002>.
 37. Geber A, Hitchcock CA, Swartz JE, Pullen FS, Marsden KE, Kwon-Chung KJ, Bennett JE. 1995. Deletion of the *Candida glabrata* ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. *Antimicrob Agents Chemother* 39:2708–2717. <https://doi.org/10.1128/AAC.39.12.2708>.
 38. Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, Schumacher U, Einsele H. 1997. Resistance to fluconazole and crossresistance to amphotericin B in *Candida albicans* from AIDS patients caused by defective sterol delta 5,6-desaturation. *FEBS Lett* 400:80–82. [https://doi.org/10.1016/s0014-5793\(96\)01360-9](https://doi.org/10.1016/s0014-5793(96)01360-9).
 39. Young LY, Hull CM, Heitman J. 2003. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in *Candida lusitanae*. *Antimicrob*

- Agents Chemother 47:2717–2724. <https://doi.org/10.1128/AAC.47.9.2717-2724.2003>.
40. Kannan A, Asner SA, Trachsel E, Kelly S, Parker J, Sanglard D. 2019. Comparative genomics for the elucidation of multidrug resistance in *Candida lusitanae*. *mBio* 10:e02512-19. <https://doi.org/10.1128/mBio.02512-19>.
 41. Lortholary O, Renaudat C, Sitbon K, Desnos-Ollivier M, Bretagne S, Dromer F, French Mycosis Study Group. 2017. The risk and clinical outcome of candidemia depending on underlying malignancy. *Intensive Care Med* 43:652–662. <https://doi.org/10.1007/s00134-017-4743-y>.
 42. Khan ZU, Al-Sweih NA, Ahmad S, Al-Kazemi N, Khan S, Joseph L, Chandy R. 2007. Outbreak of fungemia among neonates caused by *Candida haemulonii* resistant to amphotericin B, itraconazole, and fluconazole. *J Clin Microbiol* 45:2025–2027. <https://doi.org/10.1128/JCM.00222-07>.
 43. Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S. 2013. Fitness trade-offs restrict the evolution of resistance to amphotericin B. *PLoS Biol* 11:e1001692. <https://doi.org/10.1371/journal.pbio.1001692>.
 44. Kumar A, Prakash A, Singh A, Kumar H, Hagen F, Meis JF, Chowdhary A. 2016. *Candida haemulonii* species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. *Emerg Microbes Infect* 5:e49. <https://doi.org/10.1038/emi.2016.49>.
 45. Ahmad S, Khan Z, Al-Sweih N, Alfouzan W, Joseph L. 2020. *Candida auris* in various hospitals across Kuwait and their susceptibility and molecular basis of resistance to antifungal drugs. *Mycoses* 63:104–112. <https://doi.org/10.1111/myc.13022>.
 46. Chen XF, Zhang H, Jia XM, Cao J, Li L, Hu XL, Li N, Xiao YL, Xia F, Ye LY, Hu QF, Wu XL, Ning LP, Hsueh PR, Fan X, Yu SY, Huang JJ, Xie XL, Yang WH, Li YX, Zhang G, Zhang JJ, Duan SM, Kang W, Wang T, Li J, Xiao M, Hou X, Xu YC. 2022. Antifungal susceptibility profiles and drug resistance mechanisms of clinical *Candida duobushaemulonii* isolates from China. *Front Microbiol* 13:1001845. <https://doi.org/10.3389/fmicb.2022.1001845>.
 47. Hull CM, Bader O, Parker JE, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL. 2012. Two clinical isolates of *Candida glabrata* exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. *Antimicrob Agents Chemother* 56:6417–6421. <https://doi.org/10.1128/AAC.01145-12>.
 48. Vandeputte P, Tronchin G, Larcher G, Ernoult E, Bergès T, Chabasse D, Bouchara JP. 2008. A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of *Candida glabrata*. *Antimicrob Agents Chemother* 52:3701–3709. <https://doi.org/10.1128/AAC.00423-08>.
 49. Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL. 2012. Facultative sterol uptake in an ergosterol-deficient clinical isolate of *Candida glabrata* harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. *Antimicrob Agents Chemother* 56:4223–4232. <https://doi.org/10.1128/AAC.06253-11>.
 50. Shin JH, Kim MN, Jang SJ, Ju MY, Kim SH, Shin MG, Suh SP, Ryang DW. 2012. Detection of amphotericin B resistance in *Candida haemulonii* and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods. *J Clin Microbiol* 50:1852–1855. <https://doi.org/10.1128/JCM.06440-11>.
 51. Ranque S, Lachaud L, Gari-Toussaint M, Michel-Nguyen A, Mallié M, Gaudart J, Bertout S. 2012. Interlaboratory reproducibility of Etest amphotericin B and caspofungin yeast susceptibility testing and comparison with the CLSI method. *J Clin Microbiol* 50:2305–2309. <https://doi.org/10.1128/JCM.00490-12>.
 52. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdhary A. 2015. Multidrug-resistant *Candida auris* misidentified as *Candida haemulonii*: characterization by matrix-assisted laser desorption/ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. *J Clin Microbiol* 53:1823–1830. <https://doi.org/10.1128/JCM.00367-15>.
 53. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. 2003. *Candida albicans* mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. *Antimicrob Agents Chemother* 47:2404–2412. <https://doi.org/10.1128/AAC.47.8.2404-2412.2003>.
 54. Siopi M, Peroukidou I, Beredaki M-I, Spruijtenburg B, de Groot T, Meis JF, Vrioni G, Tsakris A, Pournaras S, Meletiadis J. 2023. Overestimation of amphotericin B resistance in *Candida auris* with Sensititre YeastOne antifungal susceptibility testing: a need for adjustment for correct interpretation. *Microbiol Spectr* 10:e0443122. <https://doi.org/10.1128/spectrum.04431-22>.
 55. Vandeputte P, Tronchin G, Bergès T, Hennequin C, Chabasse D, Bouchara JP. 2007. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of *Candida glabrata* with pseudohyphal growth. *Antimicrob Agents Chemother* 51:982–990. <https://doi.org/10.1128/AAC.01510-06>.
 56. Elias D, Toth HN, Jacko J, Morvova M, Valachovic M, Gbelska Y. 2022. Erg6p is essential for antifungal drug resistance, plasma membrane properties and cell wall integrity in *Candida glabrata*. *FEMS Yeast Res* 21:foac045. <https://doi.org/10.1093/femsyr/foac045>.
 57. Kordalewska M, Guerrero KD, Mikulski TD, Elias TN, Garcia-Rubio R, Berrio I, Gardam D, Heath CH, Chowdhary A, Govender NP. 2021. Rare modification in the ergosterol biosynthesis pathway leads to amphotericin B resistance in *Candida auris* clinical isolates. *bioRxiv*. <https://doi.org/10.1101/2021.10.22.465535>.
 58. Muller C, Aldejohn AM, Kurzai O, Martin R. 2021. Sterol profiling as a prediction tool for the identification of antifungal drug resistance. *Mycoses* 65(Suppl 1):24.
 59. Alobaid K, Ahmad S, Asadzadeh M, Mokaddas E, Al-Sweih N, Albenwan K, Alfouzan W, Al-Obaid I, Jeragh A, Al-Roomi E, Khan Z, Joseph L, Varghese S. 2021. Epidemiology of candidemia in Kuwait: a nationwide, population-based study. *J Fungi* 7:673. <https://doi.org/10.3390/jof7080673>.
 60. Asadzadeh M, Ahmad S, Hagen F, Meis JF, Al-Sweih N, Khan Z. 2015. Simple, low-cost detection of *Candida parapsilosis* complex isolates and molecular fingerprinting of *Candida orthopsilosis* strains in Kuwait by ITS region sequencing and amplified fragment length polymorphism analysis. *PLoS One* 10:e0142880. <https://doi.org/10.1371/journal.pone.0142880>.
 61. Khan ZU, Ahmad S, Hagen F, Fell JW, Kowshik T, Chandy T, Boekhout T. 2010. *Cryptococcus randhawai* sp. nov., a novel anamorphic basidiomycetous yeast isolated from tree trunk hollow of *Ficus religiosa* (peepal tree) from New Delhi, India. *Antonie Van Leeuwenhoek* 97:253–259. <https://doi.org/10.1007/s10482-009-9406-8>.
 62. Asadzadeh M, Ahmad S, Al-Sweih N, Khan Z. 2017. Epidemiology and molecular basis of resistance to fluconazole among clinical *Candida parapsilosis* isolates in Kuwait. *Microb Drug Resist* 23:966–972. <https://doi.org/10.1089/mdr.2016.0336>.
 63. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. 2019. Twenty years of the SENTRY Antifungal Surveillance Program: results for *Candida* species from 1997–2016. *Open Forum Infect Dis* 6:S79–S94. <https://doi.org/10.1093/ofid/ofy358>.